Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: citric acid; stearic acid; pregelatinised maize starch; maize starch; microcrystalline cellulose; silicon dioxide; purified talc - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: purified talc; stearic acid; citric acid; silicon dioxide; microcrystalline cellulose; pregelatinised maize starch; maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; microcrystalline cellulose; stearic acid; purified talc; maize starch; citric acid; pregelatinised maize starch - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rasagiline mesilate, quantity: 1.56 mg - tablet, uncoated - excipient ingredients: silicon dioxide; pregelatinised maize starch; citric acid; maize starch; stearic acid; microcrystalline cellulose; purified talc - rasagiline is indicated for the symptomatic treatment of idiopathic parkinsons disease (pd) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Singapore - English - HSA (Health Sciences Authority)

lundbeck singapore pte. ltd. - rasagiline mesylate 1.56mg equivalent rasagiline - tablet - rasagiline mesylate 1.56mg equivalent rasagiline 1 mg

Malta - English - Medicines Authority

ascend gmbh c/o pollux business center gmbh sebastian-kneipp-straße 41, 60439 frankfurt am main, germany - tablet - rasagiline 1 mg - anti-parkinson drugs

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - azilect is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - rasalect is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline mesylate 1 mg - azilect (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. the effectiveness of azilect was demonstrated in patients with early parkinson's disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy. the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinson's disease who were treated with levodopa. enter section text here azilect is contraindicated for use with meperidine. serious adverse reactions have been precipitated with concomitant use of meperidine (e.g., demerol and other tradenames) and mao inhibitors (maois) including selective mao-b inhibitors. these adverse reactions are often described as "serotonin syndrome", a potentially serious condition, which can result in death. typical clinical signs and symptoms include behavioral and cognitive/mental status changes (e.g., confusion, hypomania

United States - English - NLM (National Library of Medicine)

teva neuroscience, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - azilect (rasagiline tablets) is indicated for the treatment of parkinson’s disease (pd). azilect is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of azilect and initiation of treatment with these medications. azilect is contraindicated for use with st. john’s wort and with cyclobenzaprine. azilect is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of azilect in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in combination